Additionally, they demonstrated that selectively inhibiting the HBP enzyme GFPT2 led to reduced growth of KRAS/LKB1 co-mutant tumor cells in culture, xenografts, and genetically modified mice. This evidence concerns the gene GFPT2 and neoplasm.